Findeisen KE, Sewell J, Ostor AJ. Biological therapies for rheumatoid arthritis: an overview for the clinician. Biologics: Targets and Therapy. 2021;15:343–52. https://doi.org/10.2147/BTT.S252575.

Priyarega S, Natarajan R. An overview of biosimilars for cancer, diabetes mellitus, rheumatoid arthritis and other immune-mediated diseases approved between 2016 and 2021. Results Chem. 2022;4: 100356. https://doi.org/10.1016/j.rechem.2022.100356.

Article  CAS  Google Scholar 

Singh S, Murad MH, Fumery M, Sedano R, Jairath V, Panaccione R, et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(12):1002–14. https://doi.org/10.1016/S2468-1253(21)00312-5.

Article  PubMed  PubMed Central  Google Scholar 

Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52: 151939. https://doi.org/10.1016/j.semarthrit.2021.11.009.

Article  PubMed  CAS  Google Scholar 

Mulcahy A, Buttorff C, Finegold K, El-Kilani Z, Oliver JF, Murphy S, Jessup A. Projected US savings from biosimilars, 2021–2025. Am J Manag Care. 2022;28(7):329–35. https://doi.org/10.37765/ajmc.2022.88809.

Chen H-H, Yemeke T, Ozawa S. Reduction of biologic pricing following biosimilar introduction: analysis across 57 countries and regions, 2012–19. PLoS One. 2024;19(6): e0304851. https://doi.org/10.1371/journal.pone.0304851.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Moorkens E, Vulto AG, Huys I, Dylst P, Godman B, Keuerleber S, et al. Policies for biosimilar uptake in Europe: an overview. PLoS One. 2017;12(12): e0190147. https://doi.org/10.1371/journal.pone.0190147.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Woo H, Shin G, Lee D, Kwon H-Y, Bae S. Is the availability of biosimilar adalimumab associated with budget savings? A difference-in-difference analysis of 14 countries. BioDrugs. 2024;38(1):133–44. https://doi.org/10.1007/s40259-023-00636-z.

Article  PubMed  CAS  Google Scholar 

Povero M, Pradelli L. Funding innovation thanks to anti-TNF-α biosimilars uptake: the economic impact in Italy. Farmeconomia. Health economics and therapeutic pathways. 2020;21(1):37–47. https://doi.org/10.7175/fe.v21i1.1449.

Moorkens E, Godman B, Huys I, Hoxha I, Malaj A, Keuerleber S, et al. The expiry of Humira® market exclusivity and the entry of adalimumab biosimilars in Europe: an overview of pricing and national policy measures. Front Pharmacol. 2021;11: 591134. https://doi.org/10.3389/fphar.2020.591134.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Shin G, Kim BS, Kim DY, Bae S. Unveiling the biosimilar paradox of oncologists’ perceptions and hesitations in South Korea: a web-based survey study. BioDrugs. 2024;38:301–11. https://doi.org/10.1007/s40259-023-00640-3.

Machado S, Cruz A, Ferreira PL, Morais C, Pimenta RE. Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review. Front Public Health. 2024;12:1263472. https://doi.org/10.3389/fpubh.2024.1263472.

Article  PubMed  PubMed Central  Google Scholar 

Chhabra H, Mouslim MC, Kashiramka S, Rathore AS. Dynamics of biosimilar uptake in emerging markets. Expert Opin Biol Ther. 2022;22(6):679–88. https://doi.org/10.1080/14712598.2022.2076557.

Article  PubMed  Google Scholar 

Kim Y, Kwon H-Y, Godman B, Moorkens E, Simoens S, Bae S. Uptake of biosimilar infliximab in the UK, France, Japan, and Korea: budget savings or market expansion across countries? Front Pharmacol. 2020;11: 529600. https://doi.org/10.3389/fphar.2020.00970.

Article  CAS  Google Scholar 

England NHS. Commissioning framework for biological medicines (including biosimilar medicines). 2017. https://www.england.nhs.uk/publication/commissioning-framework-for-biological-medicines/. Accessed 14 Mar 2025.

Mestre-Ferrandiz J, Czech M, Smolen JS, Cornes P, Aapro MS, Danese S, et al. Capturing the holistic value of biosimilars in Europe-Part 1: a historical perspective. Expert Rev Pharmacoecon Outcomes Res. 2024;24(2):237–50. https://doi.org/10.1080/14737167.2023.2297926.

Article  PubMed  Google Scholar 

Jarrion Q, Azzouz B, Robinson J, Jolly D, Vallet C, Trenque T. Penetration rate of anti-TNF biosimilars and savings at 5 years after their introduction in French hospitals. Therapies. 2022;77(4):467–75. https://doi.org/10.1016/j.therap.2021.10.012.

Article  Google Scholar 

IQVIA. 2021 ACTS Annual Report. 2022. https://www.iqvia.com/library/publications/acts-2021. Accessed 14 Mar 2025.

Danzon PM, Furukawa MF. Cross-national evidence on generic pharmaceuticals: pharmacy vs. physician-driven markets. National Bureau of Economic Research Working Paper Series. 2011 Jul; No. 17226. https://doi.org/10.3386/w17226.

Diao Y, Qian J, Liu Y, Zhou Y, Wang Y, Ma H, et al. How government insurance coverage changed the utilization and affordability of expensive targeted anti-cancer medicines in China: an interrupted time-series study. J Glob Health. 2019;9(2):020603. https://doi.org/10.7189/jogh.09.020603.

Schieber LZ, Guy GP, Seth P, Young R, Mattson CL, Mikosz CA, Schieber RA. Trends and patterns of geographic variation in opioid prescribing practices by state, United States, 2006–2017. JAMA Netw Open. 2019;2(3):e190665–e190665. https://doi.org/10.1001/jamanetworkopen.2019.0665.

Article  PubMed  PubMed Central  Google Scholar 

Board PMPR. NDPUIS source materials. 2023. https://www.canada.ca/en/patented-medicine-prices-review/services/npduis/source-materials.html. Accessed 14 Mar 2025.

Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, Laxminarayan R. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014;14(8):742–50. https://doi.org/10.1016/S1473-3099(14)70780-7.

Article  PubMed  Google Scholar 

Brink M, Kahle XU, Vermaat JS, Zijlstra JM, Chamuleau M, Kersten MJ, et al. Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study. Blood Adv. 2021;5(15):2958–64. https://doi.org/10.1182/bloodadvances.2021004295.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cazap E, Jacobs I, McBride A, Popovian R, Sikora K. Global acceptance of biosimilars: importance of regulatory consistency, education, and trust. Oncologist. 2018;23(10):1188–98. https://doi.org/10.1634/theoncologist.2017-0671.

Article  PubMed  PubMed Central  Google Scholar 

Konstantinidou S, Papaspiliou A, Kokkotou E. Current and future roles of biosimilars in oncology practice. Oncol Lett. 2020;19(1):45–51. https://doi.org/10.3892/ol.2019.11105.

Article  PubMed  CAS  Google Scholar 

Thévenon O. Family policies in OECD countries: a comparative analysis. Popul Dev Rev. 2011;37(1):57–87. https://doi.org/10.1111/j.1728-4457.2011.00390.x.

Article  PubMed  Google Scholar 

Cooper AF. The G20 and regional dynamics. 2011. Colin I. Bradford. https://www.kdi.re.kr/upload/15230/2-2.pdf. Accessed 14 Mar 2025.

Moorkens E, Simoens S, Troein P, Declerck P, Vulto AG, Huys I. Different policy measures and practices between Swedish counties influence market dynamics: part 1—biosimilar and originator infliximab in the hospital setting. BioDrugs. 2019;33:285–97. https://doi.org/10.1007/s40259-019-00345-6.

Article  PubMed  PubMed Central  Google Scholar 

Moorkens E, Simoens S, Troein P, Declerck P, Vulto AG, Huys I. Different policy measures and practices between Swedish counties influence market dynamics: part 2—biosimilar and originator etanercept in the outpatient setting. BioDrugs. 2019;33:299–306. https://doi.org/10.1007/s40259-019-00346-5.

Article  PubMed  PubMed Central  Google Scholar 

Rémuzat C, Kapuśniak A, Caban A, Ionescu D, Radière G, Mendoza C, Toumi M. Supply-side and demand-side policies for biosimilars: an overview in 10 European member states. J Mark Access Health Policy. 2017;5(1):1307315. https://doi.org/10.1080/20016689.2017.1307315.

Article  PubMed  PubMed Central  Google Scholar 

Renwick MJ, Smolina K, Gladstone EJ, Weymann D, Morgan SG. Postmarket policy considerations for biosimilar oncology drugs. Lancet Oncol. 2016;17(1):e31–8. https://doi.org/10.1016/S1470-2045(15)00381-2.

Article  PubMed  Google Scholar 

Vogler S, Schneider P. Do pricing and usage-enhancing policies differ between biosimilars and generics? Findings from an international survey. GaBI J. 2017;6(2):79–88. https://doi.org/10.5639/gabij.2017.0602.015.

Article  Google Scholar 

Vogler S, Schneider P, Zuba M, Busse R, Panteli D. Policies to encourage the use of biosimilars in European countries and their potential impact on pharmaceutical expenditure. Front Pharmacol. 2021;12: 625296. https://doi.org/10.3389/fphar.2021.625296.

Article  PubMed  PubMed Central  Google Scholar 

Blankart KE, Arndt F. Physician-level cost control measures and regional variation of biosimilar utilization in Germany. Int J Environ Res Public Health. 2020;17(11):4113. https://doi.org/10.3390/ijerph17114113.

Article  PubMed  PubMed Central